Sexton Biotechnologies announced that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.

Sexton Biotechnologies products include the CellSeal platform of containers and fill systems and the Stemulate®, n-Liven PR®, and T-Liven PRTM human platelet lysate (hPL) products. CellSeal is based around the benefits of a rigid, cryo-compatible closed vial and the flexibility to fit into cell and gene therapy processing methods.

Read More